Исследование ASCOT и его значение в формировании новой стратегии в лечении артериальной гипертонии

1. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
2. Kaplan NM, Clinical Hypertension. Philadelphia, PA: Lippincott, Williams & Wilkins, 2006.
3. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
4. РМОАГ/ВНОК. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр), 2010. 
5. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981–97.
6. Sever PS, Dahlof B, Poulter NR et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906. 
7. The CAFE investigators, for the ASCOT investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
8. Dolan EA, Stanton AVB, Parker KH et al. on behalh of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts caediovascular events in treated hypertensive patients – ASCOT substudy. J Hypertension 2009; 27: 876–85.
9. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905. 
10. Rothwell PM, Howard SC, Dolan E et al.; on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of b-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469–80.
11. Poulter NR, Sever PS, Dahlof B, Wedel H. ASCOT sub-studes. In: Anglo-Scandinavian Cardiac Outcomes Trial. Latest perspectives on this landmark trial. 3-rd edition. Published by Sherborne Gibbs Ltd 2011: 35–45. 
12. Lindgren P, Kahan T, Poulter N et al., on behalf of the ASCOT investigators. Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. Eur J Health Econ 2007; 8 (1): 25–30.
13. Lindgren P, Buxton M, Kahan T et al. on behalf of the ASCOT trial investigators. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart 2008; 94 (2): e4. Epub 2007 Oct 4.
14. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update. NICE clinical guideline. London: Royal College of Physicians 2006.
15. Sever PS. A new analysis of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Late-breaking clinical-trial session European Meeting on Hypertension 2011, Milan.
16. Sever PS and Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J 2011 doi: 10.1093/eurheartj/ehr177.
17. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. NEJM 2008; 359: 2417–28.

Ю.А.Карпов 

Институт кардиологии им. А.Л.Мясникова 
ФГУ РКНПК Минздравсоцразвития РФ